Allogene Therapeutics Announces Participation in February Investor Conferences
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company focused on developing allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, has announced its participation in the Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12, at 12:20 PM PT/3:20 PM ET. Webcasts will be available on the company's website under the Investors tab, with replays accessible for approximately 30 days after the event.
Allogene Therapeutics (Nasdaq: ALLO), un'azienda biotecnologica in fase clinica impegnata nello sviluppo di prodotti CAR T allogenici (AlloCAR T™) per il trattamento del cancro e delle malattie autoimmuni, ha annunciato la sua partecipazione alla 35ª Conferenza Annuale Oppenheimer sulla Salute e le Scienze della Vita. La presentazione è programmata per mercoledì 12 febbraio, alle 12:20 PT/15:20 ET. Le webcast saranno disponibili sul sito web dell'azienda nella sezione Investitori, con la possibilità di rivedere le trasmissioni per circa 30 giorni dopo l'evento.
Allogene Therapeutics (Nasdaq: ALLO), una empresa de biotecnología en etapa clínica centrada en el desarrollo de productos CAR T alogénicos (AlloCAR T™) para el cáncer y enfermedades autoinmunes, ha anunciado su participación en la 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer. La presentación está programada para el miércoles 12 de febrero a las 12:20 PM PT/3:20 PM ET. Las transmisiones estarán disponibles en el sitio web de la empresa en la pestaña de Inversores, con repeticiones accesibles durante aproximadamente 30 días después del evento.
Allogene Therapeutics (Nasdaq: ALLO)는 암 및 자가면역질환을 치료하기 위해 모든ogeneic CAR T (AlloCAR T™) 제품 개발에 집중하는 임상 단계 생명공학 회사로, Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여한다고 발표했습니다. 발표는 2월 12일 수요일 오후 12:20 PT/오후 3:20 ET로 예정되어 있습니다. 웹캐스트는 회사 웹사이트의 투자자 탭에서 이용 가능하며, 이벤트 이후 약 30일 동안 다시 볼 수 있습니다.
Allogene Therapeutics (Nasdaq: ALLO), une entreprise de biotechnologie en phase clinique spécialisée dans le développement de produits CAR T allogéniques (AlloCAR T™) pour le cancer et les maladies auto-immunes, a annoncé sa participation à la 35ème Conférence Annuelle Oppenheimer sur les Sciences de la Vie et la Santé. La présentation est prévue pour le mercredi 12 février à 12h20 PT/15h20 ET. Les webcasts seront disponibles sur le site internet de l'entreprise dans l'onglet Investisseurs, avec des rediffusions accessibles pendant environ 30 jours après l'événement.
Allogene Therapeutics (Nasdaq: ALLO), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von allogenen CAR T (AlloCAR T™) Produkten für Krebs und autoimmune Erkrankungen konzentriert, hat seine Teilnahme an der 35. jährlichen Konferenz für Gesundheits- und Lebenswissenschaften von Oppenheimer angekündigt. Die Präsentation ist für Mittwoch, den 12. Februar, um 12:20 PM PT/3:20 PM ET geplant. Webcasts werden auf der Unternehmenswebsite unter dem Investoren-Tab verfügbar sein, mit Wiederholungen, die etwa 30 Tage nach der Veranstaltung zugänglich sind.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in February.
Oppenheimer 35th Annual Healthcare Life Sciences Conference
Wednesday, February 12
12:20PM PT/3:20PM ET
Any available webcasts will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.
Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com
FAQ
When is Allogene Therapeutics (ALLO) presenting at the Oppenheimer Healthcare Conference 2025?
Where can investors watch Allogene Therapeutics' (ALLO) Oppenheimer conference presentation?
What therapeutic areas does Allogene Therapeutics (ALLO) focus on?
